Use of Antipsychotic Medications in Pediatric Populations: What do the Data Say?
- 548 Downloads
Recent reports of antipsychotic medication use in pediatric populations describe large increases in rates of use. Much interest in the increasing use has focused on potentially inappropriate prescribing for non-Food and Drug Administration-approved uses and use amongst youth with no mental health diagnosis. Different studies of antipsychotic use have used different time periods, geographic and insurance populations of youth, and aggregations of diagnoses. We review recent estimates of use and comment on the similarities and dissimilarities in rates of use. We also report new data obtained on 11 health maintenance organizations that are members of the Mental Health Research Network in order to update and extend the knowledge base on use by diagnostic indication. Results indicate that most use in pediatric populations is for disruptive behaviors and not psychotic disorders. Differences in estimates are likely a function of differences in methodology; however, there is remarkable consistency in estimates of use by diagnosis.
KeywordsAntipsychotics Children Adolescents Medicaid Mental Health Research Network Off-label MarketScan IMS Health NAMCS NDTI NCS-A
Research reported in this publication was supported by the National Institute of Mental Health (NIMH) (grant: U19MH092201). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH). Christine Stewart, Enid M. Hunkeler, Jeanne M. Madden, Rebecca C. Rossom, Christine Y. Lu, Frances L. Lynch, Beth E. Waitzfelder, Karen A. Coleman, and Gregory E. Simon have received research support from NIMH. John E. Zeber has received research support and support for travel from National Institutes of Health (NIH).
Compliance with Ethics Guidelines
Conflict of Interest
Robert B. Penfold has received research support from Bristol-Meyers Squibb, and NIMH.
Christine Stewart has received funding through NIMH.
Enid M. Hunkeler has patent applications pending for an individualized health care management system and a computer-implemented method for assisting a care partner in monitoring a patient with a chronic disease and has received funding through NIMH.
Jeanne M. Madden has received research support from NIH, FDA, Agency for Healthcare Research and Quality and NIMH.
Janet R. Cummings has received funding through NIMH.
Ashli A. Owen-Smith has received funding through NIMH.
Rebecca C. Rossom has received funding through NIMH.
Christine Y. Lu has received funding through NIMH.
Frances L. Lynch has received funding through NIMH.
Beth E. Waitzfelder has received funding through NIMH.
Karen A. Coleman has received research support from NIMH, NIH, and Patient Centered Outcomes Research Institute.
Brian K. Ahmedani has received research support from NIMH.
Arne L. Beck and has received funding through NIMH.
John E. Zeber has received research support from VA Health Services Research & Development, the Commonwealth Fund, NIH and NIMH.
Gregory E. Simon has received research support from Bristol-Myers Squibb and NIMH.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.• Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69:1247–56. The article presents antipsychotic utilization estimates between 1993 and 2009 using nationally representative NAMCS data. Estimates are based on visits where a prescription occurred. Excellent discussion of reasons for practice variation in prescribing and increasing use over time.PubMedCrossRefGoogle Scholar
- 3.• Andrade SE, Lo JC, Roblin D, Fouayzi H, Connor DF, Penfold RB, et al. Antipsychotic medication use among children and risk of diabetes mellitus. Pediatrics. 2011;128:1135–41. Study reports an almost fourfold increase in the rate of diabetes among youth using antipsychotic medications compared to youth using no psychotropic medications.PubMedCrossRefGoogle Scholar
- 5.• Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21:517–35. Review of 34 published head-to-head and placebo-controlled studies in youth with psychotic and bipolar disorders of the effects of antipsychotic medications on weight and metabolic disorders. Describes metabolic effects and number-needed-to-harm for individual agents.PubMedCrossRefGoogle Scholar
- 7.• Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics. 2012;129:e771–84. Reviews the comparative effectiveness of individual agents for youth across 64 trials and 17 cohort studies.PubMedCrossRefGoogle Scholar
- 9.• McKinney C, Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. Clin Psychol Rev. 2011;31:465–71. Discusses mechanisms of action and long-term outcomes for young people using antipsychotics. Good discussion of use for sedation rather than core reasons for disruptive behavior.PubMedCrossRefGoogle Scholar
- 13.• Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20:177–84. Only recent study estimating use from physician-reported prescribing. Categorizes the volume of off-label use by level of evidence.PubMedCentralPubMedCrossRefGoogle Scholar
- 15.Aman MG, Gharabawi GM, Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental R, Developmental D. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. J Clin Psychiatry. 2004;65:1197–210.PubMedCrossRefGoogle Scholar
- 20.•• Matone M, Localio R, Huang YS, Dosreis S, Feudtner C, Rubin D. The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. medicaid-enrolled children. Health Serv Res. 2012;47:1836–60. Comprehensive presentation of utilization rates in youth across 50 states and 6 years. Detailed rates available for young people aged 0–5, 6–11, and 12–18 years.PubMedCrossRefGoogle Scholar
- 26.• Olfson M, He JP, Merikangas KR. Psychotropic medication treatment of adolescents: results from the national comorbidity survey-adolescent supplement. J Am Acad Child Adolesc Psychiatry. 2013;52:378–88. Estimates rates of antipsychotic use in youth across socio-demographic groups. Diagnoses were obtained using a validated instrument rather than administrative codes.PubMedCrossRefGoogle Scholar
- 28.Solomon DH, Stedman M, Licari A, Weinblatt ME, Maher N, Shadick N. Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries. Arthritis Rheum. 2007;57:234–9.PubMedCrossRefGoogle Scholar